Shield Therapeutics
STX · AIM · Health Care · mcap £63m · 5.3p
| Date | Type | Announcement | Day |
|---|---|---|---|
| 30 Sep 26 | Routine | Total Voting Rights | |
| 01 Sep 26 | Routine | Total Voting Rights | |
| 27 Aug 26 | Shield assumes full control of ACCRUFeR® in the US
Shield assumes full control of ACCRUFeR® in the US |
+11.1% | |
| 20 Aug 26 | Results | Half-year Results
Interim results for the six months ended 30 June 2026 |
+11.4% |
| 03 Aug 26 | Routine | Total Voting Rights | |
| 30 Jul 26 | Trading update | Q2 and H1 2026 Trading Update
Q2 revenues of $11.9M with strong growth in the commercial segment |
−23.5% |
| 28 Jul 26 | ACCRUFeR® Phase 3 pediatric trial published
ACCRUFeR® Phase 3 pediatric trial published in Pediatric Drugs |
+1.8% | |
| 30 Jun 26 | Routine | Block Listing 6 Monthly Return | |
| 18 Jun 26 | Result of AGM
London, UK, 18 June 2026: Shield Therapeutics plc (LSE: STX), a commercial stage pharmaceutical company specialising in iron deficiency with or without anemia ("ID/IDA"), announces the voting results for each resolution |
+0.0% | |
| 29 May 26 | Routine | Total Voting Rights | |
| 05 May 26 | Grant of Share Options
London, UK, 05 May 2026: Shield Therapeutics plc (LSE: STX), a commercial stage pharmaceutical company specialising in iron deficiency, announces that on 04 May 2026 it granted share awards in the form of options over or |
−11.4% | |
| 01 May 26 | Trading update | Q1 2026 Trading Update
Group net revenues of $18M with strong year on year ACCRUFeR® net revenue growth of 54% to $9.9M |
−9.7% |
| 30 Apr 26 | Routine | Total Voting Rights | |
| 27 Apr 26 | Enrollment in Phase II Clinical Trial for ACCRUFeR
Enrollment commenced in Phase II Clinical Trial for ACCRUFeR® (Ferric Maltol) in Japan. |
+0.0% | |
| 09 Apr 26 | Results | Audited results for year ended 31 December 2025
Audited results for the year ended 31 December 2025 |
+2.3% |
| 01 Apr 26 | Publication of Report, Reinforcing FDA Approval
Publication of Report in Pediatric Drugs, Reinforcing FDA Approval Milestone |
+13.3% | |
| 31 Mar 26 | Routine | Total Voting Rights | |
| 31 Mar 26 | EMA approves extension - to include adolescents
European Medicines Agency approves extension of the indication to include adolescents |
+5.3% | |
| 03 Mar 26 | Chinese NMPA Accepts MAA Submission for ACCRUFeR®
Chinese NMPA Accepts MAA Submission for ACCRUFeR® (ferric maltol) |
−4.1% | |
| 27 Feb 26 | Routine | Total Voting Rights | |
| 09 Feb 26 | FDA Grants additional Exclusivity for ACCRUFeR
US FDA Grants additional 3 Years Exclusivity for ACCRUFeR® |
+14.6% | |
| 30 Jan 26 | Routine | Total Voting Rights | |
| 30 Jan 26 | Approval for ACCRUFeR in China expected in Q1 2026
Filing for marketing authorisation for the approval for ACCRUFeR® in China |
−2.3% | |
| 21 Jan 26 | Trading update | Q4 2025 Trading Update
Generated positive Cash flow in Q4 2025 with Total Group Revenues of c. |
−4.9% |
| 02 Jan 26 | Routine | Block listing 6 Monthly Return | |
| 02 Jan 26 | Routine | Total Voting Rights | |
| 22 Dec 25 | FDA approves extension for ACCRUFeR®
US FDA approves extension of the indication for ACCRUFeR® to include |
−2.2% | |
| 18 Dec 25 | Routine | Block Listing Application | |
| 11 Dec 25 | Shield Wins Gold at Titan Branding Awards
Shield Therapeutics Wins Gold at Titan Branding Awards for ACCRUFeR's Brand Transformation |
+0.5% | |
| 03 Dec 25 | Amends Senior Secured Debt Financing
Amends Senior Secured Debt Financing with improved terms |
+5.4% | |
| 14 Nov 25 | Initiation of a Phase II Clinical Trial in Japan
Initiation of a Phase II Clinical Trial for ACCRUFeR® (Ferric Maltol) for the |
+0.7% | |
| 11 Nov 25 | Results | ACCRUFeR Pediatric PK Results to be Presented
ACCRUFeR® Pediatric Pharmacokinetic (PK) Results Will be Presented at the American Society of Hematology (ASH) Conference |
+3.0% |
| 07 Nov 25 | ACCRUFeR receives Authorisation by Korean Ministry
ACCRUFeR® receives Marketing Authorisation by Korean Ministry of Food and Drug Safety (MFDS) |
+1.5% | |
| 23 Oct 25 | Trading update | Q3 2025 Trading Update
$13.1m net revenues and an average net selling price of $237 |
+4.1% |
| 14 Oct 25 | Board change | Grant of Share Options to Chief Executive Officer
Grant of Share Options to Chief Executive Officer |
−1.2% |
Company filings. Not investment advice.